Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relugolix - Sumitomo Pharma America/Takeda

Drug Profile

Relugolix - Sumitomo Pharma America/Takeda

Alternative Names: MVT-601 - Sumitomo Pharma America/Takeda; ORGOVYX; Relumina; RVT 601; T-1331285; TAK-385

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer ASKA Pharmaceutical; Sumitomo Pharma America; Takeda; Takeda Oncology
  • Class Analgesics; Antineoplastics; Fluorobenzenes; Ketones; Pyridazines; Pyrimidines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Registered Endometriosis; Uterine leiomyoma
  • Phase II Pain
  • No development reported Solid tumours

Most Recent Events

  • 12 Mar 2024 Launched for Prostate cancer (Late-stage disease, Metastatic disease) in Canada (PO)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO, Tablet)
  • 23 Oct 2023 Sumitomo Pharma plans to launch relugolix for Prostate cancer in Canada in Q1 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top